NDA 021415 · Galderma Labs Lp
Metvixia
Methyl Aminolevulinate Hydrochloride · Topical
DiscontinuedLast checked: Nov 20, 2026Latest source record: Nov 20, 2012 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Jul 27, 2004
Approved uses
2
Original approval plus efficacy supplements
Registered trials
50
15 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 26, 2008 Supplement 3 · Efficacy LetterLabel
- Jul 27, 2004 Original approval · Type 3 - New Dosage Form ReviewLetterLabel
1 products under this application
- METVIXIA · METHYL AMINOLEVULINATE HYDROCHLORIDE EQ 16.8% BASE · CREAM, TOPICAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Methyl Aminolevulinate" as an intervention, any sponsor and status, largest first.
- Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic TherapyPivotal-lookingCompleted
Biofrontera Bioscience GmbHIndustry
NCT02799069 · 571 participants · Start Apr 2008 · Primary completion Aug 2009
Drug: BF-200 ALA; MAL Cream and 1 more · For: Actinic Keratosis
- Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the FacePivotal-lookingCompleted
Galderma R&DIndustry
NCT04085367 · 557 participants · Start Sep 30, 2019 · Primary completion Mar 3, 2021
Drug: MAL 16.8% cream; MAL Vehicle Cream · For: Actinic Keratoses
Sites: Tucson, Arizona; Fort Smith, Arkansas; Encinitas, California · 60 sites in all
- Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic TherapyPivotal-lookingCompleted
Biofrontera Bioscience GmbHIndustry
NCT02144077 · 281 participants · Start Jan 28, 2014 · Primary completion Nov 17, 2015
Drug: BF-200 ALA; methyl-aminolevulinate · For: Basal Cell Carcinoma (BCC)
Sites: Recklinghausen, Germany
- New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)Pivotal-lookingCompleted
Norwegian University of Science and TechnologyAcademic, hospital or other
NCT01482104 · 277 participants · Start Jun 2012 · Primary completion Oct 2017
Drug: MAL-PDT re-treatment; usual MAL-PDT · For: Skin Neoplasms; Carcinoma, Basal Cell
Sites: Bergen, Norway; Førde, Norway; Lillehammer, Norway · 9 sites in all
- Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's DiseasePivotal-lookingCompleted
Maastricht University Medical CenterAcademic, hospital or other
NCT03909646 · 250 participants · Start May 27, 2019 · Primary completion Mar 2, 2022
Drug: Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram; 5Fluorouracil · For: Bowen's Disease
Sites: Maastricht, Netherlands
- Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage MethylaminolevulinatePivotal-lookingStatus unknown
Maastricht University Medical CenterAcademic, hospital or other
NCT01491711 · 162 participants (planned) · Start Aug 2013 · Primary completion Apr 2015
Drug: Methylaminolevulinate PDT in 2 sessions; Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT · For: Superficial Basal Cell Carcinoma
Sites: Maastricht, Netherlands; Venlo, Netherlands; Rotterdam, Netherlands
- Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe AcnePivotal-lookingCompleted
PhotocureIndustry
NCT00594425 · 150 participants · Start Feb 2007 · Primary completion Jul 2008
Drug: Methyl aminolevulinate (MAL) PDT · For: Acne Vulgaris
Sites: San Diego, California; Vallejo, California; Naperville, Illinois · 14 sites in all
- Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic KeratosesPivotal-lookingCompleted
Galderma R&DIndustry
NCT01821391 · 131 participants · Start Jul 2013 · Primary completion Jan 2014
Drug: NDL-PDT; c-PDT and 1 more · For: Actinic Keratoses
Sites: Montpellier, France; Nantes, France; Nice, France · 18 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Italian expert consensus paper on the management of patients with actinic keratoses.
Moscarella E, Di Brizzi EV, Casari A, et al. · Dermatol Ther 2020 · Systematic Review, Consensus Statement
- The emerging role of photodynamic therapy in the treatment of cutaneous infections.
Anagu O, Salas J, Choe S, et al. · Ital J Dermatol Venerol 2025 · Systematic Review
- Long-term follow-up results of a pilot study for nodular basal cell carcinoma with PDT using partial home treatment protocol.
Salvio AG, Stringasci MD, Requena MB, et al. · Photodiagnosis Photodyn Ther 2024 · Randomized Controlled Trial
- Systematic Literature Review and Network Meta-analysis of the Efficacy and Acceptability of Interventions in Actinic Keratoses.
Ezzedine K, Painchault C, Brignone M · Acta Derm Venereol 2021 · Systematic Review, Network Meta-Analysis
- [Plaque-phase mycosis fungoides treated with photodynamic therapy: results from 12 patients].
Fernández-Guarino M, Harto A, Pérez-García B, et al. · Actas Dermosifiliogr 2010 · Clinical Trial
- Photodynamic therapy in the treatment of rosacea: A systematic review.
Li A, Fang R, Mao X, et al. · Photodiagnosis Photodyn Ther 2022 · Systematic Review
Sponsor: Galderma Labs Lp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.